By Stephen Nakrosis
The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23.
After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.
Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 18, 2024 19:11 ET (00:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.